Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

BioScience Health Innovations (BHIC) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for BioScience Health Innovations (BHIC) over the last 3 years, with Q3 2025 value amounting to 0.78%.

  • BioScience Health Innovations' EBITDA Margin fell 105900.0% to 0.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.74%, marking a year-over-year increase of 162300.0%. This contributed to the annual value of 4.72% for FY2024, which is 468000.0% up from last year.
  • Per BioScience Health Innovations' latest filing, its EBITDA Margin stood at 0.78% for Q3 2025, which was down 105900.0% from 26.04% recorded in Q2 2025.
  • BioScience Health Innovations' 5-year EBITDA Margin high stood at 34.78% for Q1 2025, and its period low was 218.68% during Q1 2023.
  • For the 3-year period, BioScience Health Innovations' EBITDA Margin averaged around 28.38%, with its median value being 0.78% (2025).
  • Per our database at Business Quant, BioScience Health Innovations' EBITDA Margin soared by 1994600bps in 2024 and then tumbled by -105900bps in 2025.
  • Over the past 3 years, BioScience Health Innovations' EBITDA Margin (Quarter) stood at 12.64% in 2023, then skyrocketed by 113bps to 1.63% in 2024, then crashed by -148bps to 0.78% in 2025.
  • Its EBITDA Margin was 0.78% in Q3 2025, compared to 26.04% in Q2 2025 and 34.78% in Q1 2025.